SCHEMBL16432196

SCHEMBL16432196

c1ccc(Oc2ccc(Oc3ncnc4cc[nH]c34)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 3/20 0.55
EGFR P00533 8/20 0.48
ERBB2 P04626 7/20 0.48
ERBB3 P21860 7/20 0.48
ERBB4 Q15303 7/20 0.48
DYRK1A Q13627 1/20 0.45
TTBK1 Q5TCY1 1/20 0.45
TTBK2 Q6IQ55 1/20 0.45
KDR P35968 1/20 0.41
TEK Q02763 1/20 0.41
TSHR P16473 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MRGPRX1 Q96LB2 1/20 0.38
LTA4H P09960 1/20 0.38
THRB P10828 1/20 0.38
MAP3K7 O43318 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16432224 0.82 ERBB2 (0.46) TRPA1EGFRERBB2ERBB3ERBB4
SCHEMBL16432121 0.79 EGFR (0.71) EGFRERBB2ERBB3ERBB4TTBK1
SCHEMBL16433189 0.77 LTA4H (0.44) TRPA1EGFRKDRTEKTSHR
SCHEMBL4001800 0.75 CDC7 (0.60) EGFRERBB2ERBB3ERBB4DYRK1A
SCHEMBL4290591 0.75 DYRK1A (0.45) TRPA1EGFRERBB2ERBB3ERBB4
SCHEMBL15612939 0.73 DYRK1A (0.53) TRPA1EGFRERBB2ERBB3ERBB4
SCHEMBL6435658 0.71 ERBB2 (0.47) TRPA1EGFRERBB2ERBB3ERBB4
SCHEMBL2748271 0.71 MEN1 (0.43) TRPA1EGFRKDRTSHRNPC1
SCHEMBL3979754 0.69 EGFR (0.69) TRPA1EGFRKDRTEKTSHR
SCHEMBL252692 0.68 TRPA1 (0.58) TRPA1EGFRTSHRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105814057-B Pyrimidines, pyridines and pyrazines as BTK inhibitors and uses thereof 默克专利有限公司 2019-05-03 CN disclosed
EP-3049417-B1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2018-10-17 EP disclosed
US-10005784-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2018-06-26 US disclosed
US-10005784-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2018-06-26 US disclosed
US-9738648-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2017-08-22 US disclosed
US-9738648-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2017-08-22 US disclosed
US-20170226113-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-08-10 US disclosed
US-20170226113-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-08-10 US disclosed
EP-3049417-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2016-08-03 EP disclosed
CN-105814057-A Pyrimidines, pyridines and pyrazines as BTK inhibitors and uses thereof 默克专利有限公司 2016-07-27 CN disclosed
US-20160159804-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-06-09 US disclosed
US-20160159804-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-06-09 US disclosed
WO-2015017502-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2015-02-05 WO disclosed
WO-2015017502-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2015-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226113-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN TRPA1 1872/4885EGFR 1018/4885ERBB2 139/4885
US-20160159804-A1 PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN TRPA1 1872/4885EGFR 1018/4885ERBB2 139/4885
US-10005784-B2 Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof BTK, SYK, LYN TRPA1 2180/4885EGFR 1046/4885ERBB2 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.